This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (76)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic

Anju Nohria, MD; Eldrin Lewis, MD; Lynne Warner Stevenson, MD

JAMA. 2002;287:628-640.

Context  Advanced heart failure, defined as persistence of limiting symptoms despite therapy with agents of proven efficacy, accounts for the majority of morbidity and mortality in heart failure.

Objective  To review current medical therapy for advanced heart failure.

Data Sources  We searched MEDLINE for all articles containing the term advanced heart failure that were published between 1980 and 2001; EMBASE was searched from 1987-1999, Best Evidence from 1991-1998, and Evidence-Based Medicine from 1995-1999. The Cochrane Library also was searched for critical reviews and meta-analyses of congestive heart failure.

Study Selection  Randomized controlled trials of therapy for 150 patients or more were included if advanced heart failure was represented. Other common clinical situations were addressed from smaller trials as available, trials of milder heart failure, consensus guidelines, and both published and personal clinical experience.

Data Extraction  Data quality was determined by publication in peer-reviewed literature or inclusion in professional society guidelines.

Data Synthesis  A primary focus for care of advanced heart failure is ongoing identification and treatment of the elevated filling pressures that cause disabling symptoms. While angiotensin-converting enzyme inhibitors and -adrenergic agents can slow disease progression and prolong survival, titration and tolerability often present challenges. Most patients are not eligible for surgical intervention but do benefit from a medical regimen tailored to individual clinical and hemodynamic profiles and from heart failure management programs that reduce rehospitalization. Survival ranges from 80% at 2 years for patients rendered free of congestion to less than 50% at 6 months for patients with refractory symptoms, in whom end-of-life options may include hospice care and inactivation of implantable defibrillators.

Conclusions  Current management of advanced heart failure is based more on consensus than on randomized trials. Systematic investigation should address not only new therapies but also strategies for selecting and optimizing therapies already available.

Author Affiliation: Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass.

RELATED ARTICLES

February 6, 2002
JAMA. 2002;287(5):655-656.
EXTRACT | FULL TEXT  

Heart Failure
JAMA. 2002;287(5):676.
PDF  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Surgical therapy for ischemic heart failure: Single-center experience with surgical anterior ventricular restoration
Menicanti et al.
J. Thorac. Cardiovasc. Surg. 2007;134:433-441.
ABSTRACT | FULL TEXT  

Improving Communication at the Transition to Home Health Care: Use of an Electronic Referral System
Siegler et al.
Home Health Care Management Practice 2007;19:267-271.
ABSTRACT  

Fc{gamma} Receptors IIa on Cardiomyocytes and Their Potential Functional Relevance in Dilated Cardiomyopathy
Staudt et al.
J Am Coll Cardiol 2007;49:1684-1692.
ABSTRACT | FULL TEXT  

Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships
Givertz et al.
Circulation 2007;115:1218-1224.
ABSTRACT | FULL TEXT  

Reverse remodelling in heart failure with cardiac resynchronisation therapy
Sutton and Keane
Heart 2007;93:167-171.
ABSTRACT | FULL TEXT  

Beneficial Hemodynamic and Clinical Effects of Surgical Ventricular Restoration in Patients With Ischemic Dilated Cardiomyopathy
Tulner et al.
Ann. Thorac. Surg. 2006;82:1721-1727.
ABSTRACT | FULL TEXT  

Desperately Seeking a Randomized Clinical Trial of Resynchronization Therapy for Patients With Heart Failure and Atrial Fibrillation
Steinberg
J Am Coll Cardiol 2006;48:744-746.
FULL TEXT  

Hemodynamic Goals Are Relevant
Stevenson et al.
Circulation 2006;113:1020-1033.
FULL TEXT  

Continuous Aortic Flow Augmentation: A Pilot Study of Hemodynamic and Renal Responses to a Novel Percutaneous Intervention in Decompensated Heart Failure
Konstam et al.
Circulation 2005;112:3107-3114.
ABSTRACT | FULL TEXT  

Ventricular Assist Devices for Durable Support
Stevenson and Shekar
Circulation 2005;112:e111-e115.
FULL TEXT  

Acute Decompensated Heart Failure: The Shrinking Role of Inotropic Therapy
Dec
J Am Coll Cardiol 2005;46:65-67.
FULL TEXT  

Torrent or Torment From the Tubules?: Challenge of the Cardiorenal Connections
Stevenson et al.
J Am Coll Cardiol 2005;45:2004-2007.
FULL TEXT  

Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond
Mann and Bristow
Circulation 2005;111:2837-2849.
FULL TEXT  

Palliation of heart failure
Davis et al.
AM J HOSP PALLIAT CARE 2005;22:211-222.
ABSTRACT  

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology
Endorsed by the European Society of Intensive Care et al.
Eur Heart J 2005;26:384-416.
FULL TEXT  

Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials
Yan et al.
ANN INTERN MED 2005;142:132-145.
ABSTRACT | FULL TEXT  

Heart failure case disease management program: a pilot study of home telemonitoring versus usual care
Capomolla et al.
Eur Heart J Suppl 2004;6:F91-F98.
ABSTRACT | FULL TEXT  

Thoughts of patients with advanced heart failure on dying
Willems et al.
Palliat Med 2004;18:564-572.
ABSTRACT  

Adverse Effects of {beta}-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials
Ko et al.
Arch Intern Med 2004;164:1389-1394.
ABSTRACT | FULL TEXT  

Guidelines for Acute Decompensated Heart Failure Treatment
DiDomenico et al.
The Annals of Pharmacotherapy 2004;38:649-660.
ABSTRACT | FULL TEXT  

Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone
de Denus et al.
Chest 2004;125:652-668.
ABSTRACT | FULL TEXT  

Hemodynamic unloading of the failing left ventricle using an arterial-to-arterial extracorporeal flow circuit
Haithcock et al.
Ann. Thorac. Surg. 2004;77:158-163.
ABSTRACT | FULL TEXT  

Reversal of Refractory Congestive Heart Failure after Thiamine Supplementation: Report of a Case and Review of Literature
Mendoza et al.
J CARDIOVASC PHARMACOL THER 2003;8:313-316.
ABSTRACT  

Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward? Part I: Inotropic Infusions During Hospitalization
Stevenson
Circulation 2003;108:367-372.
FULL TEXT  

Nitroprusside in Critically Ill Patients with Left Ventricular Dysfunction and Aortic Stenosis
Khot et al.
NEJM 2003;348:1756-1763.
ABSTRACT | FULL TEXT  

Nitroxyl gets to the heart of the matter
Feelisch
Proc. Natl. Acad. Sci. USA 2003;100:4978-4980.
FULL TEXT  

ATS/ACCP Statement on Cardiopulmonary Exercise Testing
Am. J. Respir. Crit. Care Med. 2003;167:211-277.
FULL TEXT  

Immunoadsorption as a new therapeutic principle for treatment of dilated cardiomyopathy
Felix et al.
Eur Heart J Suppl 2002;4:I63-I68.
ABSTRACT  

Treatment of Congestive Heart Failure
Brumley et al.
JAMA 2002;287:2209-2210.
FULL TEXT